The Pharma Data

MARCH 20, 2021

Sponsors and CROs will continue to be eager to bounce back and accelerate the drug development process after significant delays caused by the pandemic,” Reites said. . These focus areas will materialize in study designs as hybrid decentralized approaches that support global programs,” Reites said. “In Source link: [link].

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

pharmaphorum

APRIL 6, 2021

Join over 28 world-class speakers to see how classic and next-gen tumor models can be leveraged to expand your mechanism of action understanding, model the complexities of the tumor microenvironment, and guide your clinical design. Aaron Goldman , Director, Drug Resistance Group, Harvard Medical School.

In-Vivo 52

In-Vivo Clinical Design Scientist Medicine 52

Advarra

JUNE 28, 2022

As a drug successfully makes it through the development process, sponsors will inevitably need to submit a new drug application (NDA) to the Food and Drug Administration (FDA). Failure to Have a Pre-Investigational New Drug (IND) Meeting. Failure to Have a Pre-Investigational New Drug (IND) Meeting.

Regulation 52

Regulation Drugs Manufacturing Development 52